Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy
Status:
Completed
Trial end date:
2018-02-07
Target enrollment:
Participant gender:
Summary
This Phase 3 study will investigate the efficacy, safety and tolerability of an oral daily
dose of 20 mg or 80 mg tafamidis meglumine capsules compared to placebo in subjects with
either transthyretin genetic variants or wild-type transthyretin resulting in amyloid
cardiomyopathy.